Titlebook: Chemotherapy for Leukemia; Novel Drugs and Trea Takanori Ueda Book 2017 Springer Nature Singapore Pte Ltd. 2017 Acute promyelocytic leukemi

削減

Imatinib: Clinical Pharmacology and Therapeutic Resultsssion-free survival and overall survival associated with imatinib therapy (400 mg daily) have ranged between 83–94% and 83–97%, respectively. Imatinib is generally well tolerated, and adverse events are typically manageable. Current evidence does not support the extensive use of high-dose imatinib (

MURKY

Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Other TKIsce and intolerance to imatinib are frequently reported, particularly in patients with advanced-stage disease; this leads to around 30% of CML patients discontinuing imatinib treatment. Point mutations within the . kinase domain, which interfere with imatinib binding, are the most critical cause of i

清澈

Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Basic Results and Pharmacokineticsms of action of rituximab include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis. The influences of CD20 expression level, circulating soluble CD20, Fcγ receptor (FcγR) polymorphisms, complement regulatory proteins, and C1qA-276 p

Obscure

白楊魚

自制

增長(zhǎng)

FLT3 Inhibitorson is the most frequent genetic alteration in acute myeloid leukemia (AML) and is associated with poor prognosis in AML patients. Since high-dose chemotherapy including allogeneic hematopoietic stem cell transplantation cannot overcome a poor prognosis, development of FLT3 inhibitor is highly expect

刺穿

Retinoic Acid, All-, Retinoic Acid (ATRA), and Tamibaroteneete remission (CR) in patients with acute promyelocytic leukemia (APL). Although introduction of ATRA as a differentiating agent has been a major breakthrough in the treatment of APL, ATRA is currently recognized as a molecular-targeted therapy directed at the PML-RARα chimeric protein, which is gen

patriarch

書法